<DOC>
	<DOCNO>NCT01133704</DOCNO>
	<brief_summary>This randomize , double blind , placebo control trial immunotherapy autologous antigen-loaded dendritic cell ( Provenge , APC8015 ) asymptomatic , metastatic , hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Immunotherapy With APC8015 ( Sipuleucel-T , Provenge ) Asymptomatic , Metastatic , Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Histologically document adenocarcinoma prostate Metastatic disease evidence soft tissue and/or bony metastasis Prostatespecific antigen value least 5 ng/mL Tumor progression hormonal therapy Castration level testosterone ( define less 50 ng/dL ) Life expectancy least 16 week Adequate hematologic , renal , liver function Visceral organ metastases Metastatic disease expect need radiation therapy within 4 month . Concurrent therapy experimental agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>asymptomatic metastatic hormone-refractory prostate cancer</keyword>
</DOC>